表紙
市場調査レポート

転移性黒色腫:パイプライン分析

Metastatic Melanoma - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 229728
出版日 ページ情報 英文 675 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
転移性黒色腫:パイプライン分析 Metastatic Melanoma - Pipeline Review, H1 2016
出版日: 2016年04月13日 ページ情報: 英文 675 Pages
概要

転移性黒色腫(別名:IV期黒色腫)とは、あらゆる種類の黒色腫細胞(皮膚・粘膜・眼窩内など)がリンパ節を経由して人体組織の各所に転移した状態のことを指します。特に肝臓・肺・骨・脳に転移する可能性が高くなっています。主な症状として、リンパ節の腫脹(特に腋下・鼠径部)や、原因不明の体重減少、頭痛、てんかん発作などが挙げられます。主な治療法として、外科手術や放射線治療、化学療法、およびそれらの複合療法などがあります。

当レポートでは、世界各国での転移性黒色腫治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

転移性黒色腫の概要

治療薬の開発

  • 転移性黒色腫向けパイプライン製品:概要
  • 転移性黒色腫向けパイプライン製品:比較分析

各企業で開発中の転移性黒色腫治療薬

大学/研究機関で研究中の転移性黒色腫治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

転移性黒色腫治療薬:開発中の製品の一覧(企業別)

転移性黒色腫治療薬:研究中の製品の一覧(大学/研究機関別)

転移性黒色腫治療薬の開発に従事している企業

転移性黒色腫:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

転移性黒色腫治療薬:パイプライン製品の最新動向

転移性黒色腫治療薬:開発が休止状態の製品

転移性黒色腫治療薬:開発が中止された製品

転移性黒色腫関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7691IDB

Summary

Global Markets Direct's, 'Metastatic Melanoma - Pipeline Review, H1 2016', provides an overview of the Metastatic Melanoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Melanoma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Melanoma
  • The report reviews pipeline therapeutics for Metastatic Melanoma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Metastatic Melanoma therapeutics and enlists all their major and minor projects
  • The report assesses Metastatic Melanoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Metastatic Melanoma

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Melanoma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Metastatic Melanoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Metastatic Melanoma Overview
  • Therapeutics Development
  • Metastatic Melanoma - Therapeutics under Development by Companies
  • Metastatic Melanoma - Therapeutics under Investigation by Universities/Institutes
  • Metastatic Melanoma - Pipeline Products Glance
  • Metastatic Melanoma - Products under Development by Companies
  • Metastatic Melanoma - Products under Investigation by Universities/Institutes
  • Metastatic Melanoma - Companies Involved in Therapeutics Development
  • Metastatic Melanoma - Therapeutics Assessment
  • Drug Profiles
  • Metastatic Melanoma - Recent Pipeline Updates
  • Metastatic Melanoma - Dormant Projects
  • Metastatic Melanoma - Discontinued Products
  • Metastatic Melanoma - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Metastatic Melanoma, H1 2016
  • Number of Products under Development for Metastatic Melanoma - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Metastatic Melanoma - Pipeline by AB Science SA, H1 2016
  • Metastatic Melanoma - Pipeline by AbbVie Inc., H1 2016
  • Metastatic Melanoma - Pipeline by Adaptimmune Therapeutics Plc, H1 2016
  • Metastatic Melanoma - Pipeline by Affichem SA, H1 2016
  • Metastatic Melanoma - Pipeline by Agalimmune Ltd, H1 2016
  • Metastatic Melanoma - Pipeline by Agenus, Inc., H1 2016
  • Metastatic Melanoma - Pipeline by AGV Discovery, SAS, H1 2016
  • Metastatic Melanoma - Pipeline by Altor BioScience Corporation, H1 2016
  • Metastatic Melanoma - Pipeline by Amgen Inc., H1 2016
  • Metastatic Melanoma - Pipeline by Angimmune LLC, H1 2016
  • Metastatic Melanoma - Pipeline by Apexigen, Inc., H1 2016
  • Metastatic Melanoma - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2016
  • Metastatic Melanoma - Pipeline by Array BioPharma Inc., H1 2016
  • Metastatic Melanoma - Pipeline by Astex Pharmaceuticals, Inc., H1 2016
  • Metastatic Melanoma - Pipeline by AstraZeneca Plc, H1 2016
  • Metastatic Melanoma - Pipeline by Basilea Pharmaceutica AG, H1 2016
  • Metastatic Melanoma - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016
  • Metastatic Melanoma - Pipeline by Bioncotech Therapeutics S.L., H1 2016
  • Metastatic Melanoma - Pipeline by Bionomics Limited, H1 2016
  • Metastatic Melanoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Metastatic Melanoma - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Metastatic Melanoma - Pipeline by Cellceutix Corporation, H1 2016
  • Metastatic Melanoma - Pipeline by Celldex Therapeutics, Inc., H1 2016
  • Metastatic Melanoma - Pipeline by Cortice Biosciences, Inc., H1 2016
  • Metastatic Melanoma - Pipeline by Delcath Systems, Inc., H1 2016
  • Metastatic Melanoma - Pipeline by Digna Biotech, S.L., H1 2016
  • Metastatic Melanoma - Pipeline by DNA Therapeutics S.A., H1 2016
  • Metastatic Melanoma - Pipeline by Dynavax Technologies Corporation, H1 2016
  • Metastatic Melanoma - Pipeline by Eisai Co., Ltd., H1 2016
  • Metastatic Melanoma - Pipeline by Eli Lilly and Company, H1 2016
  • Metastatic Melanoma - Pipeline by Ensol Biosciences Inc., H1 2016
  • Metastatic Melanoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Metastatic Melanoma - Pipeline by Galapagos NV, H1 2016
  • Metastatic Melanoma - Pipeline by Galectin Therapeutics, Inc., H1 2016
  • Metastatic Melanoma - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Metastatic Melanoma - Pipeline by Idera Pharmaceuticals, Inc., H1 2016
  • Metastatic Melanoma - Pipeline by Immune Design Corp., H1 2016
  • Metastatic Melanoma - Pipeline by Immunocore Limited, H1 2016
  • Metastatic Melanoma - Pipeline by ImmuRx, Inc., H1 2016
  • Metastatic Melanoma - Pipeline by Incyte Corporation, H1 2016
  • Metastatic Melanoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016
  • Metastatic Melanoma - Pipeline by IO Biotech ApS, H1 2016
  • Metastatic Melanoma - Pipeline by Life Science Pharmaceuticals, Incorporated, H1 2016
  • Metastatic Melanoma - Pipeline by Lipotek Pty Ltd., H1 2016
  • Metastatic Melanoma - Pipeline by Luitpold Pharmaceuticals, Inc., H1 2016
  • Metastatic Melanoma - Pipeline by MacroGenics, Inc., H1 2016
  • Metastatic Melanoma - Pipeline by MedImmune, LLC, H1 2016
  • Metastatic Melanoma - Pipeline by Medivation, Inc., H1 2016
  • Metastatic Melanoma - Pipeline by MELEMA Pharma GmbH , H1 2016
  • Metastatic Melanoma - Pipeline by Merck & Co., Inc., H1 2016
  • Metastatic Melanoma - Pipeline by Merck KGaA, H1 2016
  • Metastatic Melanoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016
  • Metastatic Melanoma - Pipeline by Modulate Therapeutics, Inc., H1 2016
  • Metastatic Melanoma - Pipeline by Morphotek, Inc., H1 2016
  • Metastatic Melanoma - Pipeline by NewLink Genetics Corporation, H1 2016
  • Metastatic Melanoma - Pipeline by Novartis AG, H1 2016
  • Metastatic Melanoma - Pipeline by Omeros Corporation, H1 2016
  • Metastatic Melanoma - Pipeline by Oncolytics Biotech Inc., H1 2016
  • Metastatic Melanoma - Pipeline by OncoSec Medical Incorporated, H1 2016
  • Metastatic Melanoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • Metastatic Melanoma - Pipeline by Pfizer Inc., H1 2016
  • Metastatic Melanoma - Pipeline by Pharmis Biofarmaceutica, Lda., H1 2016
  • Metastatic Melanoma - Pipeline by Philogen S.p.A., H1 2016
  • Metastatic Melanoma - Pipeline by Plexxikon Inc., H1 2016
  • Metastatic Melanoma - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016
  • Metastatic Melanoma - Pipeline by Polyphor Ltd., H1 2016
  • Metastatic Melanoma - Pipeline by Prima BioMed Ltd., H1 2016
  • Metastatic Melanoma - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2016
  • Metastatic Melanoma - Pipeline by Provenance Biopharmaceuticals Corp., H1 2016
  • Metastatic Melanoma - Pipeline by Reata Pharmaceuticals, Inc., H1 2016
  • Metastatic Melanoma - Pipeline by Recepta Biopharma S.A., H1 2016
  • Metastatic Melanoma - Pipeline by RXi Pharmaceuticals Corporation, H1 2016
  • Metastatic Melanoma - Pipeline by Scancell Holdings Plc, H1 2016
  • Metastatic Melanoma - Pipeline by Syndax Pharmaceuticals, Inc., H1 2016
  • Metastatic Melanoma - Pipeline by Takara Bio Inc., H1 2016
  • Metastatic Melanoma - Pipeline by TC BioPharm Limited, H1 2016
  • Metastatic Melanoma - Pipeline by Tikcro Technologies, Ltd., H1 2016
  • Metastatic Melanoma - Pipeline by Ultimovacs AS, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Metastatic Melanoma Therapeutics - Recent Pipeline Updates, H1 2016
  • Metastatic Melanoma - Dormant Projects, H1 2016
  • Metastatic Melanoma - Dormant Projects (Contd..1), H1 2016
  • Metastatic Melanoma - Dormant Projects (Contd..2), H1 2016
  • Metastatic Melanoma - Dormant Projects (Contd..3), H1 2016
  • Metastatic Melanoma - Dormant Projects (Contd..4), H1 2016
  • Metastatic Melanoma - Dormant Projects (Contd..5), H1 2016
  • Metastatic Melanoma - Dormant Projects (Contd..6), H1 2016
  • Metastatic Melanoma - Dormant Projects (Contd..7), H1 2016
  • Metastatic Melanoma - Dormant Projects (Contd..8), H1 2016
  • Metastatic Melanoma - Dormant Projects (Contd..9), H1 2016
  • Metastatic Melanoma - Dormant Projects (Contd..10), H1 2016
  • Metastatic Melanoma - Dormant Projects (Contd..11), H1 2016
  • Metastatic Melanoma - Discontinued Products, H1 2016
  • Metastatic Melanoma - Discontinued Products (Contd..1), H1 2016

List of Figures

  • Number of Products under Development for Metastatic Melanoma, H1 2016
  • Number of Products under Development for Metastatic Melanoma - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top